<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bone disease in diabetes mellitus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bone disease in diabetes mellitus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bone disease in diabetes mellitus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kendall F Moseley, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Deborah E Sellmeyer, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 16, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The skeleton is increasingly recognized as a site of end-organ damage in diabetes. The effects of diabetes on bone are complex and an area of active investigation. While most studies demonstrate that fracture risk is increased in both type 1 and type 2 diabetes, bone mineral density (BMD), as measured by dual-energy x-ray absorptiometry (DXA), may not reflect bone fragility or accurately predict fracture risk. This is particularly true in individuals with type 2 diabetes, in whom BMD is often normal or elevated compared with those without the disease. Our understanding of the extent to which the metabolic abnormalities of diabetes impact bone metabolism, structure, quality, and BMD is evolving. This topic will review the effects of type 1 and type 2 diabetes on bone  (
         <a class="graphic graphic_table graphicRef51539" href="/z/d/graphic/51539.html" rel="external">
          table 1
         </a>
         ). The musculoskeletal complications of diabetes are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5126.html" rel="external">
          "Overview of the musculoskeletal complications of diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         Derangements in bone metabolism that occur in diabetes-related kidney disease and other forms of chronic kidney disease are also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">
          "Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H346691031">
         <span class="h1">
          BONE FRACTURE
         </span>
        </p>
        <p class="headingAnchor" id="H3301477299">
         <span class="h2">
          Increased risk of fracture
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of epidemiologic studies have demonstrated that both type 1 and type 2 diabetes contribute to bone fragility and increase the risk of fractures  (
         <a class="graphic graphic_table graphicRef51539" href="/z/d/graphic/51539.html" rel="external">
          table 1
         </a>
         ). As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 1 diabetes
         </strong>
         – In meta-analyses of observational studies in patients with and without type 1 diabetes, patients with type 1 diabetes had an increased risk of hip, lumbar spine, and all fractures across the lifespan [
         <a href="#rid1">
          1-3
         </a>
         ]. In one meta-analysis, fractures occurred in 4.8 percent of adults aged 18 to 50 years with type 1 diabetes versus 2 percent without diabetes (pooled relative risk [RR] for all fracture 1.88, 95% CI 1.52-2.32) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 2 diabetes
         </strong>
         – In meta-analyses of observational studies in patients with and without type 2 diabetes, patients with type 2 diabetes had an increased risk of hip, vertebral, peripheral, and overall fracture (RRs ranging from 1.16 to 1.37) [
         <a href="#rid4">
          4-6
         </a>
         ]. Although both men and women with type 2 diabetes appear to have increased risk of nonvertebral and hip fracture [
         <a href="#rid7">
          7,8
         </a>
         ], data from a prospective cohort study (men aged ≥65 years) showed no difference in the prevalence and incidence of vertebral fractures between men with and without type 2 diabetes [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Type 1 and type 2 diabetes may not confer equivalent fracture risk. Although both are associated with a relatively increased risk of hip fracture compared with individuals without diabetes, meta-analyses and systematic reviews suggest that the magnitude of increase in hip fracture risk attributable to the presence of diabetes is greater in individuals with type 1 diabetes (RR 6.3-6.94) than in those with type 2 diabetes (RR 1.38-1.7) [
         <a href="#rid8">
          8,10
         </a>
         ]. This differential magnitude of increased risk may, in part, reflect the higher prevalence of diabetes-related risk factors for fracture in type 1 compared with type 2 diabetes (eg, vascular complications, longer duration of disease). (See
         <a class="local">
          'Diabetes-related risk factors'
         </a>
         below.)
        </p>
        <p>
         Prolonged fracture healing also has been described in both type 1 and type 2 diabetes [
         <a href="#rid11">
          11,12
         </a>
         ]. In a systematic review of studies evaluating complications of fracture healing, patients with diabetes and surgically treated lower extremity fractures had increased rates of malunion, infection, and reoperation compared with patients without diabetes [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H559687305">
         <span class="h2">
          Diabetes-related risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Population-based studies have found associations between risk of fractures (nonvertebral, vertebral, and hip) and longer diabetes duration, poor glycemic management, diabetic retinopathy, nephropathy, neuropathy, and need for insulin therapy [
         <a href="#rid13">
          13-19
         </a>
         ]. For example, in a retrospective, population-based cohort study of almost three million veterans (900,402 with diabetes), the risk of any clinical fracture (RR 1.22, 95% CI 1.21-1.23) and hip fracture (RR 1.21, 95% CI 1.19-1.23) was increased in veterans with diabetes [
         <a href="#rid20">
          20
         </a>
         ]. Peripheral neuropathy, cardiovascular disease, and congestive heart failure were associated with an increased risk of fracture. In a cross-sectional study in individuals with type 1 diabetes enrolled in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, higher mean A1C and the presence of kidney disease were inversely associated with bone mineral density (BMD) at the total hip [
         <a href="#rid21">
          21
         </a>
         ], although fracture data were not reported.
        </p>
        <p class="headingAnchor" id="H1991906194">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased bone fragility in diabetes is multifactorial. In broad terms, micro- and macrovascular complications of the disease, hormonal alterations, and diabetes treatments all contribute to diminished bone strength  (
         <a class="graphic graphic_table graphicRef51539" href="/z/d/graphic/51539.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1343353813">
         <span class="h2">
          Type 1 versus type 2 diabetes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some mechanisms underlying bone fragility are common to both type 1 and type 2 diabetes, whereas others are distinct  (
         <a class="graphic graphic_table graphicRef51539" href="/z/d/graphic/51539.html" rel="external">
          table 1
         </a>
         ). Type 1 diabetes is usually diagnosed prior to the age of peak bone accrual and is therefore more likely to affect peak bone mass. Further, as it generally develops at a younger age than type 2 diabetes, type 1 diabetes imparts longer exposure to dysregulated glucose homeostasis, with possible sequelae including earlier onset of microvascular complications, increased deposition of advanced glycation end products (AGEs), and greater glycation of collagen. Indeed, in individuals with type 1 diabetes, glycemia is inversely associated with bone mineral density (BMD) [
         <a href="#rid21">
          21
         </a>
         ]; however, clinical studies have not yet established whether improved insulin delivery systems and attendant improvements in long-term glycemia reduce the risk of bone fragility and fracture.
        </p>
        <p class="headingAnchor" id="H392542353">
         <span class="h2">
          Contributing factors
         </span>
        </p>
        <p class="headingAnchor" id="H1418977606">
         <span class="h3">
          Diabetes-related complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Micro- and macrovascular complications of diabetes can adversely affect bone health. Microvascular disease may involve the bone microvasculature and alter the bone marrow microenvironment where bone progenitor cells reside, with shifts in cellular differentiation to adipocytes rather than osteoblasts and consequent increase in bone marrow adiposity [
         <a href="#rid22">
          22
         </a>
         ]. In some studies, marrow adiposity was associated with glycated hemoglobin (A1C) level or fractures [
         <a href="#rid23">
          23-26
         </a>
         ].
        </p>
        <p>
         In a study using high-resolution peripheral quantitative computed tomography (HR-pQCT) to evaluate patients with type 2 diabetes (with and without microvascular complications) and controls, only the group with microvascular complications had cortical bone deficits [
         <a href="#rid27">
          27
         </a>
         ]. A similar study in patients with type 1 diabetes showed that the presence of microvascular complications was associated with deficits in both cortical and trabecular bone [
         <a href="#rid28">
          28
         </a>
         ]. Another HR-pQCT study suggested that microvascular disease may play a role in increased cortical porosity in patients with type 2 diabetes [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="local">
          'Bone quantity and quality'
         </a>
         below.)
        </p>
        <p>
         Patients with diabetes are at increased risk for falls compared with those without diabetes, due in part to hypoglycemic events but also to autonomic and peripheral neuropathy. Retinopathy with visual impairment may further compromise patient safety and lead to gait instability. An increased risk of falling and fall-related fractures has been reported in older women with diabetes, although these factors do not fully explain the increased fracture risk observed [
         <a href="#rid30">
          30,31
         </a>
         ]. Neuropathy may also cause localized bone loss, which may increase the risk of fracture at the foot and ankle. Diabetic kidney disease can lead to abnormal bone remodeling and/or mineralization defects, termed chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">
          "Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2007549906">
         <span class="h3">
          Diabetes therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fracture risk may also be related to diabetes pharmacotherapy. Thiazolidinediones and the sodium-glucose cotransporter 2 (SGLT2) inhibitor,
         <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">
          canagliflozin
         </a>
         , have been reported to increase the risk of fractures. The adverse effects of these drugs are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Skeletal fractures'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">
          "Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Skeletal fragility'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3367546634">
         <span class="h3">
          Insulin and other hormones
         </span>
         <span class="headingEndMark">
          —
         </span>
         Insulin has anabolic effects on bone, but the effects of elevated endogenous levels in type 2 disease (due to peripheral insulin resistance) or the effects of exogenous insulin use on bone health are unclear. Insulin requirements in type 2 diabetes often mark longstanding or progressive diabetes that can be accompanied by vascular complications and other comorbidities that contribute to fracture risk; such comorbidities therefore may confound studies evaluating the effects of insulin treatment on fracture. The anabolic effects of insulin may be mediated through the insulin-like growth factor 1 (IGF-1) pathway, and in type 1 diabetes, low levels of insulin and IGF-1 may impair osteoblast function [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         In postmenopausal women with type 2 diabetes, serum IGF-1 levels were inversely associated with the presence of vertebral fractures [
         <a href="#rid33">
          33
         </a>
         ]. In men with diabetes, hypogonadism may also contribute to bone fragility. Central hypogonadism is common in men with both type 1 and type 2 diabetes, even in the absence of obesity [
         <a href="#rid34">
          34
         </a>
         ]. Hypogonadism, in turn, may promote further adverse changes in both body composition (decreased lean mass, increased fat mass) and glucose homeostasis. Testosterone is important for bone remodeling by both directly promoting bone formation and indirectly preventing bone resorption through effects mediated after its aromatization to estradiol [
         <a href="#rid35">
          35
         </a>
         ]. Thus, central hypogonadism in men with diabetes may contribute to impaired bone strength [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Finally, vitamin D deficiency is common in adults with both type 1 and type 2 diabetes [
         <a href="#rid37">
          37
         </a>
         ]. Diabetes-related kidney disease can lead to impaired synthesis of bioactive vitamin D, with detrimental effects on bone metabolism. Skeletal consequences of vitamin D deficiency can include osteomalacia and secondary hyperparathyroidism. (See
         <a class="medical medical_review" href="/z/d/html/13915.html" rel="external">
          "Vitamin D and extraskeletal health", section on 'Diabetes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">
          "Epidemiology and etiology of osteomalacia", section on 'Vitamin D deficiency and resistance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1506931690">
         <span class="h3">
          Hyperglycemia and advanced glycation end products
         </span>
         <span class="headingEndMark">
          —
         </span>
         In chronic hyperglycemia, excess glucose combines with free amino acids on circulating or tissue proteins. This nonenzymatic process initially forms reversible, early glycation products and, later, irreversible AGEs. The accumulation of AGEs in bone matrix alters collagen structure; impacts osteoblast, osteoclast, and osteocyte number and function; and increases bone marrow adiposity and local cytokine production; all of these factors contribute to aberrant bone remodeling, bone embrittlement, and reduced bone quality [
         <a href="#rid21">
          21,23,38-40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2514879533">
         <span class="h2">
          Bone quantity and quality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both bone
         <strong>
         </strong>
         quantity and quality help determine bone strength and fracture risk. Clinically, bone quantity can be measured by dual-energy x-ray absorptiometry (DXA) as areal BMD and, less commonly, from computed tomography (CT) as volumetric BMD. Parameters of bone quality are more challenging to quantify and usually measured only in research settings. Measures of bone quality include bone structure (microarchitecture), material properties, and remodeling.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone density
         </strong>
         – Compared with the reference population, BMD is usually lower in patients with type 1 diabetes and normal or increased in patients with type 2 diabetes [
         <a href="#rid23">
          23,41,42
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a study of 60 adolescents with type 1 diabetes, total body and lumbar spine BMD Z-scores were significantly lower compared with the age- and sex-matched reference population [
         <a href="#rid43">
          43
         </a>
         ]. The onset of diabetes in adolescence may result in a decreased peak bone mass and a decrease in BMD due to a failure to acquire endosteal bone during growth [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a study of 65 adults (mean age 62.6 years) with longstanding (over 50 years), well-managed type 1 diabetes from a specialist center, Z-scores at the lumbar spine, total hip, femoral neck, and radius were normal [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a study of older, well-functioning patients with type 2 diabetes, hip and total body BMD were higher in Black and White adults with diabetes compared with their appropriate controls [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some individuals with diabetes, therefore, BMD does not appear to reflect fracture risk. Poor bone quality likely contributes to bone fragility and increased risk of fracture independent of measured BMD [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone structure
         </strong>
         – Type 1 and type 2 diabetes may have different effects on bone microarchitecture depending on bone type (ie, trabecular versus cortical) [
         <a href="#rid47">
          47
         </a>
         ]. Trabecular bone score (TBS) is an index of bone microarchitecture derived from lumbar spine DXA, and it serves as an indirect measurement of trabecular bone quality [
         <a href="#rid48">
          48
         </a>
         ]. Adults with type 1 and type 2 diabetes have a lower TBS than individuals with normal glycemia [
         <a href="#rid48">
          48-51
         </a>
         ]. In addition, TBS is a significant predictor of fracture risk independent of bone density [
         <a href="#rid49">
          49,52
         </a>
         ]. Research using HR-pQCT suggests that a deficit in cortical bone, resulting in increased cortical porosity, may contribute to fracture risk in type 2 diabetes and in part explain the reduction in bone strength that is not detected by DXA [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone material properties
         </strong>
         – Abnormal bone tissue composition (collagen and mineral) may contribute to abnormal bone mechanical properties and thus increased fragility. Compared with bone samples from healthy individuals, those collected from individuals with type 2 diabetes had increased total mineral content and increased bone stiffness yet lower resistance to nanoindentation [
         <a href="#rid55">
          55
         </a>
         ]. Similarly, an analysis of bone samples from a small cohort of patients with type 1 diabetes showed that trabecular bone mineral content was greater in individuals who had experienced fracture compared with those who had not fractured [
         <a href="#rid38">
          38
         </a>
         ]. In both types of diabetes, bone levels of AGEs are increased and may contribute to deficiencies in bone strength. (See
         <a class="local">
          'Hyperglycemia and advanced glycation end products'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone remodeling
         </strong>
         – Low bone turnover, with a reduction in unmineralized bone matrix, and increased collagen glycation may contribute to increased fragility of diabetic bone. In histomorphometric and biochemical studies in patients with diabetes, bone turnover is low with a reduction in both bone formation and, to a lesser degree, bone resorption [
         <a href="#rid23">
          23,41,56,57
         </a>
         ]. In a systematic review and meta-analysis of 66 studies evaluating bone metabolism in patients with diabetes, markers of both bone formation (osteocalcin) and resorption (C-telopeptide) were decreased in patients with type 1 and type 2 diabetes compared with controls [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2047.html" rel="external">
          "Bone physiology and biochemical markers of bone turnover"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bone turnover also may be affected by the complications of diabetes (eg, kidney failure, which can lead to a complex skeletal pathophysiology including low turnover or adynamic bone disease) [
         <a href="#rid58">
          58-60
         </a>
         ]. However, decreased bone formation can be demonstrated in patients with type 1 diabetes before the onset of clinical kidney disease, when estimated glomerular filtration rate (eGFR) is &gt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         [
         <a href="#rid61">
          61-63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H176095728">
         <span class="h1">
          APPROACH TO EVALUATION AND MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3697011049">
         <span class="h2">
          Clinical evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of fracture risk in patients with diabetes mellitus is similar to patients without diabetes, with some caveats, and includes assessment of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of clinical risk factors for fracture  (
         <a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone mineral density (BMD), with cautious interpretation. The use of BMD to predict fracture risk in patients with diabetes (particularly type 2) is problematic because the risk of fracture may be higher than that predicted by BMD T-score alone [
         <a href="#rid64">
          64-66
         </a>
         ]. (See
         <a class="local">
          'Bone quantity and quality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fracture probability using a risk assessment tool, such as
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2051" target="_blank">
          FRAX
         </a>
         . For a given FRAX score, however, the risk of fracture may be higher in patients with diabetes than in those without diabetes [
         <a href="#rid67">
          67,68
         </a>
         ]. The FRAX algorithm does not include diabetes as a risk factor; notably, one multivariate analysis suggested that the effect of type 2 diabetes on fracture risk is equivalent to adding 10 years to the patient's age using FRAX [
         <a href="#rid69">
          69
         </a>
         ]. An alternative strategy to capture this increased fracture risk is entering "yes" for the presence of rheumatoid arthritis in the FRAX algorithm [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whereas fracture risk conferred by type 1 diabetes may be estimated by answering "yes" to "secondary cause of osteoporosis" in FRAX, this strategy will not increase the predicted risk of fracture if femoral neck bone density is included in the model. Limited data exist for the predictive utility of FRAX in type 1 diabetes. In one study in adults with type 1 diabetes, FRAX score was associated with risk of major osteoporotic fracture only when "secondary cause of osteoporosis" was indicated and BMD omitted from the algorithm [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More research is required in additional population cohorts worldwide before diabetes as a risk factor can be included. Tools that may enhance estimation of fracture risk in patients with diabetes include the trabecular bone score (TBS), which is derived from lumbar spine dual-energy x-ray absorptiometry (DXA) images, and TBS-adjusted FRAX [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fracture risk assessment, including a description of FRAX, TBS, and the clinical applications of fracture risk assessment, is reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Assessment of fracture risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'New and emerging technologies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H67545556">
         <span class="h2">
          Treatment
         </span>
        </p>
        <p class="headingAnchor" id="H3811194157">
         <span class="h3">
          Lifestyle measures and diabetes pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention of chronic hyperglycemia may benefit skeletal health by reducing advanced glycation end products (AGEs), glycation of collagen, and risk of microvascular complications. Glycemic targets should be individualized, balancing the demonstrated benefits for prevention and delay of microvascular complications with the risk of hypoglycemia. Both lifestyle modifications and pharmacotherapy are important interventions to optimize glycemic management as well as overall health in patients with type 1 and type 2 diabetes. (See
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Blood glucose monitoring and target A1C'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lifestyle measures
         </strong>
         – The general recommendations regarding healthy lifestyle (exercise to improve muscle strength and reduce the risk of falls, calcium and vitamin D supplementation) are applicable to older adults with diabetes. (See
         <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">
          "Calcium and vitamin D supplementation in osteoporosis", section on 'Optimal intake'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes pharmacotherapy
         </strong>
         – Thiazolidinediones and sodium-glucose cotransporter 2 (SGLT2) inhibitors (particularly
         <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">
          canagliflozin
         </a>
         ) have been associated with an increased risk of fracture. In patients at high risk for fracture (eg, low bone density, previous fracture), thiazolidinediones should
         <strong>
          not
         </strong>
         be used, except in the rare circumstance that other glucose-lowering agents cannot be used, and SGLT2 inhibitors should be used with caution. Although bone fractures have been reported to occur more frequently only in patients taking canagliflozin, based on putative mechanisms, other SGLT2 inhibitors may also reduce bone mass and increase bone fractures. (See
         <a class="local">
          'Diabetes therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2900855218">
         <span class="h3">
          Osteoporosis pharmacotherapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection for pharmacotherapy
         </strong>
         – In addition to optimization of glycemic management, patients at high risk for fracture should receive pharmacologic therapy to improve bone health. Similar to patients without diabetes, patients with type 1 or type 2 diabetes at high risk for fracture include those with a history of fragility fracture or osteoporosis based upon BMD measurement (T-score ≤-2.5). For patients with T-scores between -1.0 and -2.5, we treat patients with a 10-year probability of fracture (using FRAX calculations adjusted to capture diabetes-related fracture risk) that meets country-specific intervention thresholds. (See
         <a class="local">
          'Clinical evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with diabetes who do not meet these criteria for pharmacotherapy, clinical judgment should be used if additional risk factors for fracture are present that are not captured in the FRAX model or bone density reporting. For example, patients at high fall risk, those actively losing bone, or those with immobility or debilitation may still merit bone pharmacotherapy [
         <a href="#rid72">
          72,73
         </a>
         ]. Treatment intervention thresholds based on FRAX are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men", section on 'Patient selection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Fracture risk assessment tool'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of pharmacologic therapy for fracture prevention
         </strong>
         – In the absence of studies specifically targeting osteoporosis therapy in individuals with diabetes, treatment should follow general guidelines for the treatment of osteoporosis. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Few studies specifically address the pharmacologic treatment of osteoporosis in individuals with diabetes. In general, individuals with diabetes constitute a small fraction of participants in clinical trials of osteoporosis treatments, necessitating analyses of pooled data. In one systematic review of nine studies (predominantly subgroup or post hoc analyses of trials evaluating
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         ,
         <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">
          risedronate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">
          raloxifene
         </a>
         , and
         <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">
          teriparatide
         </a>
         for the treatment of osteoporosis), there were similar increases in bone density and reductions in vertebral (alendronate, raloxifene) and nonvertebral (teriparatide) fracture risk in patients with and without diabetes [
         <a href="#rid74">
          74
         </a>
         ]. The majority of the patients in the trials had type 2 diabetes. In a post hoc analysis of the FREEDOM and FREEDOM extension studies comparing
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         with placebo in patients with diabetes, denosumab significantly increased BMD and decreased vertebral fracture rate compared with placebo [
         <a href="#rid75">
          75
         </a>
         ]. In a more recent analysis, pooled individual patient data (n = 96,385, 6.8 percent with type 2 diabetes) from trials of antiresorptive osteoporosis therapies (bisphosphonates, selective estrogen receptor modulators, denosumab, odanacatib) demonstrated that these medications were effective for reducing fracture risk in all participants, irrespective of diabetes status [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Serious adverse events from bisphosphonate treatment do not appear increased in patients with diabetes [
         <a href="#rid77">
          77-79
         </a>
         ]. Nonetheless, bisphosphonate use may be limited by the presence of diabetic kidney disease, as bisphosphonates are generally not recommended for individuals with creatinine clearance below 30 to 35 mL/min. This topic is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">
          "Risks of bisphosphonate therapy in patients with osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">
          "Bisphosphonate therapy for the treatment of osteoporosis", section on 'Use in chronic kidney disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fracture risk
         </strong>
         – Fracture risk is increased in individuals with both type 1 and type 2 diabetes, possibly due to factors in addition to bone mineral density (BMD), such as duration of diabetes, glycemic management, diabetes-related complications, bone quality, treatment, and risk of falling  (
         <a class="graphic graphic_table graphicRef51539" href="/z/d/graphic/51539.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Bone fracture'
         </a>
         above and
         <a class="local">
          'Contributing factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone quantity and quality
         </strong>
         – BMD, as measured by dual-energy x-ray absorptiometry (DXA), is lower in patients with type 1 diabetes and normal or increased in patients with type 2 diabetes, although deficits in bone quality may contribute to increased fracture risk for all patients with diabetes. (See
         <a class="local">
          'Bone quantity and quality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The trabecular and cortical microarchitecture of bone may be altered in patients with type 1 and type 2 diabetes and predispose patients to bone fragility. Abnormal bone tissue composition (collagen and mineral) may contribute to abnormal bone mechanical properties and thus increased fragility  (
         <a class="graphic graphic_table graphicRef51539" href="/z/d/graphic/51539.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Bone quantity and quality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diabetes pharmacotherapy
         </strong>
         – Prevention of chronic hyperglycemia may benefit skeletal health by reducing advanced glycation end products (AGEs), glycation of collagen, and risk of microvascular complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Thiazolidinediones and sodium-glucose cotransporter 2 (SGLT2) inhibitors (particularly
         <a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">
          canagliflozin
         </a>
         ) for the treatment of diabetes have been associated with an increased risk of fracture. In patients at high risk for fracture (eg, low bone density, previous fracture), thiazolidinediones should
         <strong>
          not
         </strong>
         be used (except in the rare circumstance that other glucose-lowering agents cannot be used), and SGLT2 inhibitors (particularly canagliflozin) should be used with caution. (See
         <a class="local">
          'Diabetes therapy'
         </a>
         above and
         <a class="local">
          'Lifestyle measures and diabetes pharmacotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Osteoporosis pharmacotherapy
         </strong>
         – Osteoporosis pharmacotherapy (antiresorptive and anabolic) reduces fracture risk in patients with type 1 and type 2 diabetes. In the absence of studies specifically targeting osteoporosis management in individuals with diabetes, recommendations should follow general guidelines for the treatment of osteoporosis as well as patient-specific considerations  (
         <a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Osteoporosis pharmacotherapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3835473332">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Lesley D Hordon, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Shah VN, Shah CS, Snell-Bergeon JK. Type 1 diabetes and risk of fracture: meta-analysis and review of the literature. Diabet Med 2015; 32:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thong EP, Herath M, Weber DR, et al. Fracture risk in young and middle-aged adults with type 1 diabetes mellitus: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 2018; 89:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber DR, Haynes K, Leonard MB, et al. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN). Diabetes Care 2015; 38:1913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jia P, Bao L, Chen H, et al. Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies. Osteoporos Int 2017; 28:3113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moayeri A, Mohamadpour M, Mousavi SF, et al. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag 2017; 13:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ni Y, Fan D. Diabetes mellitus is a risk factor for low bone mass-related fractures: A meta-analysis of cohort studies. Medicine (Baltimore) 2017; 96:e8811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmberg AH, Johnell O, Nilsson PM, et al. Risk factors for fragility fracture in middle age. A prospective population-based study of 33,000 men and women. Osteoporos Int 2006; 17:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Napoli N, Schwartz AV, Schafer AL, et al. Vertebral Fracture Risk in Diabetic Elderly Men: The MrOS Study. J Bone Miner Res 2018; 33:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int 2007; 18:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin C, Luyten FP, Van der Schueren B, et al. The Impact of Type 2 Diabetes on Bone Fracture Healing. Front Endocrinol (Lausanne) 2018; 9:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gortler H, Rusyn J, Godbout C, et al. Diabetes and Healing Outcomes in Lower Extremity Fractures: A Systematic Review. Injury 2018; 49:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ivers RQ, Cumming RG, Mitchell P, et al. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 2001; 24:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melton LJ 3rd, Leibson CL, Achenbach SJ, et al. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008; 23:1334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie WD, Lix LM, Prior HJ, et al. Biphasic fracture risk in diabetes: a population-based study. Bone 2007; 40:1595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li CI, Liu CS, Lin WY, et al. Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort Study. J Bone Miner Res 2015; 30:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Losada E, Soldevila B, Ali MS, et al. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study. Osteoporos Int 2018; 29:2079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumann T, Sämann A, Lodes S, et al. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. Diabet Med 2011; 28:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009; 84:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee RH, Sloane R, Pieper C, et al. Clinical Fractures Among Older Men With Diabetes Are Mediated by Diabetic Complications. J Clin Endocrinol Metab 2018; 103:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz AV, Backlund JC, de Boer IH, et al. Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. Lancet Diabetes Endocrinol 2022; 10:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr 2009; 19:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picke AK, Campbell G, Napoli N, et al. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocr Connect 2019; 8:R55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baum T, Yap SP, Karampinos DC, et al. Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus? J Magn Reson Imaging 2012; 35:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patsch JM, Li X, Baum T, et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res 2013; 28:1721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Araújo IM, Salmon CE, Nahas AK, et al. Marrow adipose tissue spectrum in obesity and type 2 diabetes mellitus. Eur J Endocrinol 2017; 176:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shanbhogue VV, Hansen S, Frost M, et al. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol 2016; 174:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shanbhogue VV, Hansen S, Frost M, et al. Bone Geometry, Volumetric Density, Microarchitecture, and Estimated Bone Strength Assessed by HR-pQCT in Adult Patients With Type 1 Diabetes Mellitus. J Bone Miner Res 2015; 30:2188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samakkarnthai P, Sfeir JG, Atkinson EJ, et al. Determinants of Bone Material Strength and Cortical Porosity in Patients with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25:1749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thong EP, Milat F, Enticott JC, et al. The diabetes-fracture association in women with type 1 and type 2 diabetes is partially mediated by falls: a 15-year longitudinal study. Osteoporos Int 2021; 32:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein S, Leroith D. Diabetes and fragility fractures - a burgeoning epidemic? Bone 2008; 43:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011; 22:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93:1834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shigehara K, Izumi K, Kadono Y, Mizokami A. Testosterone and Bone Health in Men: A Narrative Review. J Clin Med 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo V, Chen R, Armamento-Villareal R. Hypogonadism, Type-2 Diabetes Mellitus, and Bone Health: A Narrative Review. Front Endocrinol (Lausanne) 2020; 11:607240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and diabetes. Endocrinol Metab Clin North Am 2010; 39:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farlay D, Armas LA, Gineyts E, et al. Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone From Fractured Patients With Type 1 Diabetes Mellitus. J Bone Miner Res 2016; 31:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Napoli N, Chandran M, Pierroz DD, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 2017; 13:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moseley KF, Du Z, Sacher SE, et al. Advanced glycation endproducts and bone quality: practical implications for people with type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2021; 28:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev 2015; 36:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallacher SJ, Fenner JA, Fisher BM, et al. An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus. Diabet Med 1993; 10:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wierzbicka E, Swiercz A, Pludowski P, et al. Skeletal Status, Body Composition, and Glycaemic Control in Adolescents with Type 1 Diabetes Mellitus. J Diabetes Res 2018; 2018:8121634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parthasarathy LS, Khadilkar VV, Chiplonkar SA, et al. Bone status of Indian children and adolescents with type 1 diabetes mellitus. Bone 2016; 82:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddaloni E, D'Eon S, Hastings S, et al. Bone health in subjects with type 1 diabetes for more than 50 years. Acta Diabetol 2017; 54:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004; 19:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walle M, Whittier DE, Frost M, et al. Meta-analysis of Diabetes Mellitus-Associated Differences in Bone Structure Assessed by High-Resolution Peripheral Quantitative Computed Tomography. Curr Osteoporos Rep 2022; 20:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah VN, Sippl R, Joshee P, et al. Trabecular bone quality is lower in adults with type 1 diabetes and is negatively associated with insulin resistance. Osteoporos Int 2018; 29:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie WD, Aubry-Rozier B, Lamy O, et al. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab 2013; 98:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holloway KL, De Abreu LLF, Hans D, et al. Trabecular Bone Score in Men and Women with Impaired Fasting Glucose and Diabetes. Calcif Tissue Int 2018; 102:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhattacharya S, Nagendra L, Chandran M, et al. Trabecular bone score in adults with type 1 diabetes: a meta-analysis. Osteoporos Int 2024; 35:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCloskey EV, Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res 2016; 31:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95:5045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho-Pham LT, Chau PMN, Do AT, et al. Type 2 diabetes is associated with higher trabecular bone density but lower cortical bone density: the Vietnam Osteoporosis Study. Osteoporos Int 2018; 29:2059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lekkala S, Taylor EA, Hunt HB, Donnelly E. Effects of Diabetes on Bone Material Properties. Curr Osteoporos Rep 2019; 17:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hygum K, Starup-Linde J, Harsløf T, et al. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol 2017; 176:R137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manavalan JS, Cremers S, Dempster DW, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97:3240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991; 49:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andress DL, Kopp JB, Maloney NA, et al. Early deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J Med 1987; 316:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vincenti F, Arnaud SB, Recker R, et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 1984; 25:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasperk C, Georgescu C, Nawroth P. Diabetes Mellitus and Bone Metabolism. Exp Clin Endocrinol Diabetes 2017; 125:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalaitzoglou E, Popescu I, Bunn RC, et al. Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts. Curr Osteoporos Rep 2016; 14:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber DR, Schwartz G. Epidemiology of Skeletal Health in Type 1 Diabetes. Curr Osteoporos Rep 2016; 14:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz AV. Diabetes, bone and glucose-lowering agents: clinical outcomes. Diabetologia 2017; 60:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poiana C, Capatina C. Fracture Risk Assessment in Patients With Diabetes Mellitus. J Clin Densitom 2017; 20:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin MR. Skeletal fragility in diabetes. Ann N Y Acad Sci 2017; 1402:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011; 305:2184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012; 27:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie WD, Johansson H, McCloskey EV, et al. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. J Bone Miner Res 2018; 33:1923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schacter GI, Leslie WD. DXA-Based Measurements in Diabetes: Can They Predict Fracture Risk? Calcif Tissue Int 2017; 100:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Champakanath A, Keshawarz A, Pyle L, et al. Fracture risk assessment (FRAX) without BMD and risk of major osteoporotic fractures in adults with type 1 diabetes. Bone 2021; 143:115614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res 2012; 27:2231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari SL, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int 2018; 29:2585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anagnostis P, Paschou SA, Gkekas NN, et al. Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review. Endocrine 2018; 60:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari S, Eastell R, Napoli N, et al. Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. Bone 2020; 134:115268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eastell R, Vittinghoff E, Lui LY, et al. Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk. J Bone Miner Res 2022; 37:2121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keegan TH, Schwartz AV, Bauer DC, et al. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004; 27:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue D, Muraoka R, Okazaki R, et al. Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan. Calcif Tissue Int 2016; 98:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestergaard P, Rejnmark L, Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif Tissue Int 2011; 88:209.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2051 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26096918" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Type 1 diabetes and risk of fracture: meta-analysis and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29876960" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Fracture risk in young and middle-aged adults with type 1 diabetes mellitus: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26216874" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28795239" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28442913" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29390417" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diabetes mellitus is a risk factor for low bone mass-related fractures: A meta-analysis of cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16758143" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk factors for fragility fracture in middle age. A prospective population-based study of 33,000 men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17575306" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28861910" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Vertebral Fracture Risk in Diabetic Elderly Men: The MrOS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17068657" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29416527" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The Impact of Type 2 Diabetes on Bone Fracture Healing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29162268" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Diabetes and Healing Outcomes in Lower Extremity Fractures: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11423502" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Diabetes and risk of fracture: The Blue Mountains Eye Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18348689" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Fracture risk in type 2 diabetes: update of a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17392047" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Biphasic fracture risk in diabetes: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25598134" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29860664" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21395677" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19067021" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29099931" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical Fractures Among Older Men With Diabetes Are Mediated by Diabetic Complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35576955" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19392647" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Marrow fat and the bone microenvironment: developmental, functional, and pathological implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30772871" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22190287" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23558967" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27707768" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Marrow adipose tissue spectrum in obesity and type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26537860" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26096924" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bone Geometry, Volumetric Density, Microarchitecture, and Estimated Bone Strength Assessed by HR-pQCT in Adult Patients With Type 1 Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32556277" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Determinants of Bone Material Strength and Cortical Porosity in Patients with Type 2 Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12351472" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Older women with diabetes have a higher risk of falls: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33411006" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The diabetes-fracture association in women with type 1 and type 2 diabetes is partially mediated by falls: a 15-year longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18486581" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Diabetes and fragility fractures - a burgeoning epidemic?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20532480" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18319314" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Low testosterone levels are common and associated with insulin resistance in men with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33540526" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Testosterone and Bone Health in Men: A Narrative Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33537005" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Hypogonadism, Type-2 Diabetes Mellitus, and Bone Health: A Narrative Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20511061" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Vitamin D and diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26234180" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone From Fractured Patients With Type 1 Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27658727" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Mechanisms of diabetes mellitus-induced bone fragility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34183538" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Advanced glycation endproducts and bone quality: practical implications for people with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25738213" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The impact of diabetes and diabetes medications on bone health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8096168" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30250851" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Skeletal Status, Body Composition, and Glycaemic Control in Adolescents with Type 1 Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25956533" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Bone status of Indian children and adolescents with type 1 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28236093" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Bone health in subjects with type 1 diabetes for more than 50 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15176990" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36190648" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Meta-analysis of Diabetes Mellitus-Associated Differences in Bone Structure Assessed by High-Resolution Peripheral Quantitative Computed Tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29290026" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Trabecular bone quality is lower in adults with type 1 diabetes and is negatively associated with insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23341489" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : TBS (trabecular bone score) and diabetes-related fracture risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28965154" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Trabecular Bone Score in Men and Women with Impaired Fasting Glucose and Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37819402" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Trabecular bone score in adults with type 1 diabetes: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26498132" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20719835" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29967929" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Type 2 diabetes is associated with higher trabecular bone density but lower cortical bone density: the Vietnam Osteoporosis Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31713179" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Effects of Diabetes on Bone Material Properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28049653" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22740707" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Circulating osteogenic precursor cells in type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1933578" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Diabetic bone disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3807961" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Early deposition of aluminum in bone in diabetic patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6482171" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Parathyroid and bone response of the diabetic patient to uremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28073133" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Diabetes Mellitus and Bone Metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27704393" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27744554" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Epidemiology of Skeletal Health in Type 1 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28451714" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Diabetes, bone and glucose-lowering agents: clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28716499" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Fracture Risk Assessment in Patients With Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28926113" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Skeletal fragility in diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21632482" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22052532" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : FRAX underestimates fracture risk in patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29953670" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27591864" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : DXA-Based Measurements in Diabetes: Can They Predict Fracture Risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32853853" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Fracture risk assessment (FRAX) without BMD and risk of major osteoporotic fractures in adults with type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23023946" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Type 2 diabetes and bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30066131" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Diagnosis and management of bone fragility in diabetes: an emerging challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29411304" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32058020" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36065588" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15220226" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26466937" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21161194" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Are antiresorptive drugs effective against fractures in patients with diabetes?
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
